Literature DB >> 32770104

Novel multiparameter correlates of Coxiella burnetii infection and vaccination identified by longitudinal deep immune profiling.

P M Reeves1, S Raju Paul2, L Baeten3, S E Korek2, Y Yi2, J Hess2, D Sobell2, A Scholzen4, A Garritsen4, A S De Groot5,6, L Moise5,7, T Brauns2, R Bowen3, A E Sluder2, M C Poznansky8.   

Abstract

Q-fever is a flu-like illness caused by Coxiella burnetii (Cb), a highly infectious intracellular bacterium. There is an unmet need for a safe and effective vaccine for Q-fever. Correlates of immune protection to Cb infection are limited. We proposed that analysis by longitudinal high dimensional immune (HDI) profiling using mass cytometry combined with other measures of vaccination and protection could be used to identify novel correlates of effective vaccination and control of Cb infection. Using a vaccine-challenge model in HLA-DR transgenic mice, we demonstrated significant alterations in circulating T-cell and innate immune populations that distinguished vaccinated from naïve mice within 10 days, and persisted until at least 35 days post-vaccination. Following challenge, vaccinated mice exhibited reduced bacterial burden and splenomegaly, along with distinct effector T-cell and monocyte profiles. Correlation of HDI data to serological and pathological measurements was performed. Our data indicate a Th1-biased response to Cb, consistent with previous reports, and identify Ly6C, CD73, and T-bet expression in T-cell, NK-cell, and monocytic populations as distinguishing features between vaccinated and naïve mice. This study refines the understanding of the integrated immune response to Cb vaccine and challenge, which can inform the assessment of candidate vaccines for Cb.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32770104      PMCID: PMC7414860          DOI: 10.1038/s41598-020-69327-x

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  60 in total

Review 1.  Q fever.

Authors:  Neil R Parker; Jennifer H Barralet; Alan Morton Bell
Journal:  Lancet       Date:  2006-02-25       Impact factor: 79.321

Review 2.  A review of the efficacy of human Q fever vaccine registered in Australia.

Authors:  Clayton K Chiu; David N Durrheim
Journal:  N S W Public Health Bull       Date:  2007 Jul-Aug

3.  Limited humoral and cellular responses to Q fever vaccination in older adults with risk factors for chronic Q fever.

Authors:  Teske Schoffelen; Tineke Herremans; Tom Sprong; Marrigje Nabuurs-Franssen; Peter C Wever; Leo A B Joosten; Mihai G Netea; Jos W M van der Meer; Henk A Bijlmer; Marcel van Deuren
Journal:  J Infect       Date:  2013-08-22       Impact factor: 6.072

4.  Inactivation or clearance of Coxiella burnetii in rat serum samples to enable safe serological testing.

Authors:  Marieke Opsteegh; Lianne de Heer; Harold van den Berg; Joke van der Giessen
Journal:  J Basic Microbiol       Date:  2012-09-07       Impact factor: 2.281

5.  Q fever 1985-1998. Clinical and epidemiologic features of 1,383 infections.

Authors:  D Raoult; H Tissot-Dupont; C Foucault; J Gouvernet; P E Fournier; E Bernit; A Stein; M Nesri; J R Harle; P J Weiller
Journal:  Medicine (Baltimore)       Date:  2000-03       Impact factor: 1.889

Review 6.  From Q Fever to Coxiella burnetii Infection: a Paradigm Change.

Authors:  Carole Eldin; Cléa Mélenotte; Oleg Mediannikov; Eric Ghigo; Matthieu Million; Sophie Edouard; Jean-Louis Mege; Max Maurin; Didier Raoult
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 7.  Q fever: a biological weapon in your backyard.

Authors:  Miguel G Madariaga; Katayoun Rezai; Gordon M Trenholme; Robert A Weinstein
Journal:  Lancet Infect Dis       Date:  2003-11       Impact factor: 25.071

Review 8.  Q fever (coxiellosis): epidemiology and pathogenesis.

Authors:  Zerai Woldehiwet
Journal:  Res Vet Sci       Date:  2004-10       Impact factor: 2.534

9.  Immunogenicity and reactogenicity of a Q fever chemovaccine in persons professionally exposed to Q fever in Czechoslovakia.

Authors:  J Kazár; R Brezina; A Palanová; B Tvrdá; S Schramek
Journal:  Bull World Health Organ       Date:  1982       Impact factor: 9.408

10.  Vaccine prophylaxis of abattoir-associated Q fever: eight years' experience in Australian abattoirs.

Authors:  B P Marmion; R A Ormsbee; M Kyrkou; J Wright; D A Worswick; A A Izzo; A Esterman; B Feery; R A Shapiro
Journal:  Epidemiol Infect       Date:  1990-04       Impact factor: 2.451

View more
  5 in total

1.  Evaluation of a Human T Cell-Targeted Multi-Epitope Vaccine for Q Fever in Animal Models of Coxiella burnetii Immunity.

Authors:  Ann E Sluder; Susan Raju Paul; Leonard Moise; Christina Dold; Guilhem Richard; Laura Silva-Reyes; Laurie A Baeten; Anja Scholzen; Patrick M Reeves; Andrew J Pollard; Anja Garritsen; Richard A Bowen; Anne S De Groot; Christine Rollier; Mark C Poznansky
Journal:  Front Immunol       Date:  2022-05-16       Impact factor: 8.786

Review 2.  Strategies for Immunomonitoring after Vaccination and during Infection.

Authors:  Lucille Adam; Pierre Rosenbaum; Olivia Bonduelle; Behazine Combadière
Journal:  Vaccines (Basel)       Date:  2021-04-09

3.  Soluble antigens derived from Coxiella burnetii elicit protective immunity in three animal models without inducing hypersensitivity.

Authors:  Anthony E Gregory; Erin J van Schaik; Alycia P Fratzke; Kasi E Russell-Lodrigue; Christina M Farris; James E Samuel
Journal:  Cell Rep Med       Date:  2021-12-06

Review 4.  Preclinical Animal Models for Q Fever Vaccine Development.

Authors:  Mahelat Tesfamariam; Picabo Binette; Carrie Mae Long
Journal:  Front Cell Infect Microbiol       Date:  2022-02-10       Impact factor: 5.293

5.  The Route of Vaccine Administration Determines Whether Blood Neutrophils Undergo Long-Term Phenotypic Modifications.

Authors:  Yanis Feraoun; Jean-Louis Palgen; Candie Joly; Nicolas Tchitchek; Ernesto Marcos-Lopez; Nathalie Dereuddre-Bosquet; Anne-Sophie Gallouet; Vanessa Contreras; Yves Lévy; Frédéric Martinon; Roger Le Grand; Anne-Sophie Beignon
Journal:  Front Immunol       Date:  2022-01-04       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.